CO2017004545A2 - Cápsulas blandas de calcifediol - Google Patents
Cápsulas blandas de calcifediolInfo
- Publication number
- CO2017004545A2 CO2017004545A2 CONC2017/0004545A CO2017004545A CO2017004545A2 CO 2017004545 A2 CO2017004545 A2 CO 2017004545A2 CO 2017004545 A CO2017004545 A CO 2017004545A CO 2017004545 A2 CO2017004545 A2 CO 2017004545A2
- Authority
- CO
- Colombia
- Prior art keywords
- calcifediol
- softgels
- vitamin
- deficiency
- hypophosphatemia
- Prior art date
Links
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 title abstract 2
- 235000021318 Calcifediol Nutrition 0.000 title abstract 2
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 title abstract 2
- 229960004361 calcifediol Drugs 0.000 title abstract 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 1
- 208000013038 Hypocalcemia Diseases 0.000 abstract 1
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 238000005115 demineralization Methods 0.000 abstract 1
- 230000002328 demineralizing effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000705 hypocalcaemia Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 201000006409 renal osteodystrophy Diseases 0.000 abstract 1
- 208000007442 rickets Diseases 0.000 abstract 1
- 239000007901 soft capsule Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paints Or Removers (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Lubricants (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
| PCT/EP2016/052458 WO2016124724A1 (en) | 2015-02-06 | 2016-02-05 | Calcifediol soft capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017004545A2 true CO2017004545A2 (es) | 2017-08-31 |
Family
ID=52462260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0004545A CO2017004545A2 (es) | 2015-02-06 | 2017-05-05 | Cápsulas blandas de calcifediol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10525018B2 (https=) |
| EP (3) | EP3053598A1 (https=) |
| JP (2) | JP6427270B2 (https=) |
| KR (1) | KR101971384B1 (https=) |
| CN (2) | CN106999441B (https=) |
| AU (1) | AU2016214336B2 (https=) |
| BR (1) | BR112017010657B1 (https=) |
| CA (1) | CA2967170C (https=) |
| CL (1) | CL2017001335A1 (https=) |
| CO (1) | CO2017004545A2 (https=) |
| CY (1) | CY1122976T1 (https=) |
| DK (2) | DK3204047T3 (https=) |
| EA (1) | EA034821B1 (https=) |
| ES (2) | ES2941385T3 (https=) |
| HR (1) | HRP20200859T1 (https=) |
| HU (1) | HUE050133T2 (https=) |
| LT (1) | LT3204047T (https=) |
| MA (2) | MA41058B1 (https=) |
| MD (1) | MD3204047T2 (https=) |
| ME (1) | ME03739B (https=) |
| MX (1) | MX367999B (https=) |
| MY (2) | MY189432A (https=) |
| PE (1) | PE20170911A1 (https=) |
| PH (1) | PH12017501350A1 (https=) |
| PL (1) | PL3204047T3 (https=) |
| PT (1) | PT3204047T (https=) |
| RS (2) | RS64166B1 (https=) |
| SI (1) | SI3204047T1 (https=) |
| SM (1) | SMT202000278T1 (https=) |
| WO (1) | WO2016124724A1 (https=) |
| ZA (1) | ZA201703444B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
| WO2020044314A1 (en) | 2018-08-31 | 2020-03-05 | Opko Ireland Global Holdings, Ltd. | Vitamin d pediatric dosage forms, methods of making and using |
| CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| WO2021033003A1 (en) * | 2019-08-22 | 2021-02-25 | Industrial Technologies & Biotechnologies | Hormone d (vitamin d) and its derivatives for the treatment and prevention of cancer |
| CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
| CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
| CN116350598A (zh) * | 2021-12-28 | 2023-06-30 | 人福普克药业（武汉）有限公司 | 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法 |
| CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
| CN120282775A (zh) | 2022-12-14 | 2025-07-08 | R·P·谢勒技术有限公司 | 软凝胶胶囊和制备软凝胶胶囊的方法 |
| CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药（青岛）有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
| CN121466026A (zh) * | 2026-01-12 | 2026-02-06 | 厦门紫旭医药科技有限公司 | 一种双层软胶膜及其制备方法和应用与大装量胶囊 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532126A (en) * | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| AU6866900A (en) * | 1999-08-31 | 2001-03-26 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
| US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| BR0214679A (pt) | 2001-12-03 | 2004-12-14 | Novacea Inc | Composições farmacêuticas compreendendo compostos a base de vitamina d ativa |
| US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| AU2003230191A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| AU2003226148A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| SG110107A1 (en) | 2003-09-24 | 2005-04-28 | Bioxell Spa | Compound and use in treatment |
| US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
| US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| CA2570649A1 (en) | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| JP2009513567A (ja) | 2005-09-26 | 2009-04-02 | ノバセア インコーポレイティッド | 活性ビタミンｄ化合物を用いた化学療法又は放射線療法に関連する胃腸及び膀胱の疾患の予防及び治療 |
| US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| SI3095447T1 (sl) * | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
| WO2008097646A1 (en) * | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
| DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
| PL2148661T3 (pl) | 2007-04-25 | 2013-07-31 | Cytochroma Inc | Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik |
| WO2010011906A1 (en) * | 2008-07-24 | 2010-01-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
| CA2746887C (en) | 2008-12-15 | 2016-07-05 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en not_active Ceased
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 SM SM20200278T patent/SMT202000278T1/it unknown
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 HR HRP20200859TT patent/HRP20200859T1/hr unknown
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko not_active Ceased
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 MY MYPI2021001039A patent/MY199862A/en unknown
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004545A2 (es) | Cápsulas blandas de calcifediol | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| MX2017015579A (es) | Formas de dosificacion solidas de palbociclib. | |
| MX2021010033A (es) | Composiciones microencapsuladas de cannabinoides. | |
| MX2016014509A (es) | Formulacion de vitamina soluble en grasa. | |
| CL2016001154A1 (es) | Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras. | |
| PH12017502255B1 (en) | Nrf2 regulators | |
| MX2017005030A (es) | Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. | |
| MX2018002049A (es) | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. | |
| CO2017000586A2 (es) | Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| CO2017008870A2 (es) | Análogos de amilina | |
| MX392545B (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos. | |
| EA201691828A1 (ru) | Прозрачное экструдированное туалетное мыло | |
| CL2014002218A1 (es) | Compuestos derivados de cromano sustituidos, moduladores del receptor sensible al calcio (casr); procesos para prepararlos; composicion farmaceutica; y su uso para tratar, manejar y/o reducir enfermedades tales como hiperparatiroidismo, falla renal cronica, adenoma paratiroideo, hipercalemia, hiperfosfatemia y diarrea, entre otras. | |
| BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
| CL2014003565A1 (es) | Uso de 2-metileno-19-nor-(20s)-1alpha,25-dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario. | |
| MX2018000743A (es) | Granulos de manitol para compresion directa. | |
| PL3164116T3 (pl) | Kompozycje musujące zawierające kokryształy części kwasowej | |
| EA201791845A1 (ru) | Твердые формы менахинолов | |
| BR112017011285A2 (pt) | compostos intermediários para produzir ingredientes de perfumaria | |
| MX2017009608A (es) | Compuestos anticancerigenos. | |
| PH12016502311A1 (en) | Omega-3 analogues | |
| MX2015001695A (es) | Regimenes de tratamiento. | |
| BR112018071142A2 (pt) | métodos de fabricação de formulações nutricionais |